Roche’s Greenhouse Gas Reduction Targets Validated by the Science Based Targets initiative (SBTi)

2025-04-02

Roche has received the validation of its near-term and long-term greenhouse gas (GHG) reduction targets by the Science Based Targets initiative (SBTi). This achievement builds on Roche’s long-standing commitment and dedication to creating a sustainable future by setting ambitious yet realistic decarbonisation goals.

Roche is committed to reaching net zero GHG emissions across Scope 1, 2 and 3 by 2045.
To make consistent and continuous progress towards this goal Roche has committed to the following:

Near-term targets by 2029 (2022 base year)
Roche has defined near-term targets which include our most material areas of impact:*

Reduce absolute Scope 1 & 2 GHG emissions by 70%**
Reduce absolute Scope 3 GHG emissions from fuel & energy, waste from company operations and business travel by 22.5%
Reduce absolute Scope 3 GHG emissions from use of sold products and end of life of sold products by 22.5%
70% of Roche’s suppliers by emissions covering Scope 3 purchased goods and services, capital goods and upstream transportation and distribution will have science-based targets

Long-term targets by 2045 (2022 base year)

Reduce absolute Scope 1, 2 & 3 GHG emissions by 90% to achieve net zero*

Our existing commitment to reach absolute zero Scope 1 and 2 emissions by 2050 at the latest remains.

By setting science-based targets Roche aims to enhance its environmental performance. This commitment reflects Roche's belief that mitigating climate change and reducing environmental impact are essential for safeguarding human health and long-term societal well-being.

Further information on our sustainability activities can be found here: www.roche.com/sustainability

About the Science Based Target Initiative (SBTi)
The Science Based Targets initiative (SBTi) drives ambitious climate action in the private sector by enabling organisations to set science-based emissions reduction targets. The SBTi is a partnership between Carbon Disclosure Project (CDP), the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). The SBTi is the lead partner of the Business Ambition for 1.5°C campaign – an urgent call to action from a global coalition of UN agencies, business and industry leaders, mobilising companies to set net zero science-based targets in line with a 1.5°C future.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person, we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

References
*see Annual Report 2024, p. 104
**The target boundary includes land-related emissions and removals from bioenergy feedstocks.

Roche Investor Relations
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com

Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com